Mobile

A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses o...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006083-33

A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and tolerability of repeat inhaled doses of GSK233705B MgSt (inhaled twice daily for 7 days) in COPD patients.

Critère d'inclusion

  • Study is in COPD patients

Liens